Biome Diagnostics is dedicated to advancing precision medicine in the area of cancer detection and treatment through breakthrough microbiome-based products. With BiomeOne®, the company has developed an immune profiler predicting the response and immune-related adverse events of cancer immunotherapy based on the gut microbiome. The test allows oncologists to administer the most effective first-line treatment and improve the therapy response of patients. BiomeOne® has been validated in a multi-centric clinical study and medically certified as a diagnostic software in May 2022. With an accuracy of over 90%, the test is now used in 19 clinics. Biome Diagnostics is currently raising a series A so that every cancer patient gets access to BiomeOne®.
